{"product_id":"acb-vrio-analysis","title":"Aurora Cannabis Inc. (ACB): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Aurora Cannabis Inc. (ACB)'s competitive edge! This ultra-focused VRIO Analysis, distilled into the key findings of \u0026amp;O4\u0026amp;, immediately reveals whether the firm's core assets are truly Valuable, Rare, Inimitable, and Organized for lasting success. Keep reading below to see the definitive verdict on its market sustainability.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAurora Cannabis Inc. (ACB) - VRIO Analysis: Global Medical Market Access \u0026amp; Distribution Network\n\u003c\/h2\u003e\n\n\u003cp\u003eYou're looking at Aurora Cannabis Inc.'s international medical footprint, and honestly, it’s their clearest moat right now. The direct takeaway is that their established, compliant global distribution network is a major source of high-margin, defensible revenue, provided they can navigate the regulatory shifts.\u003c\/p\u003e\n\n\u003ch\u003eValue: Capturing High-Margin International Revenue\u003c\/h\u003e\n\u003cp\u003eThis network allows Aurora Cannabis to capture revenue from markets with high barriers to entry, which typically translates to better pricing power and margins. For the full fiscal year 2025, this focus delivered record annual global medical cannabis net revenue of \\$244.4 million.\u003c\/p\u003e\n\u003cp\u003eThe real juice, though, is in the international segment's contribution. In the fourth quarter of fiscal 2025, international revenue more than doubled year-over-year, making up 61% of the total global medical cannabis net revenue for that period. That's a significant shift away from domestic reliance.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the Q4 2025 medical revenue split, showing where the value is concentrated (amounts in $\\text{CA}$ Millions):\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eQ4 2025 Revenue ($\\text{CA}$ Millions)\u003c\/th\u003e\n\u003cth\u003e% of Total Medical Revenue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Medical\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e41.03\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e~60.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanadian Medical\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.75\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e~39.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eTotal Medical\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e67.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides: The $\\text{CA}$ figures don't capture the full margin benefit, but the 70% adjusted gross margin before fair value adjustments on medical cannabis in Q4 2025 speaks volumes about the quality of this revenue stream.\u003c\/p\u003e\n\n\u003ch\u003eRarity: Deep, Compliant Market Footholds\u003c\/h\u003e\n\u003cp\u003eIt's rare because securing deep, compliant access across multiple mature international jurisdictions is not something a new entrant can replicate quickly. Aurora Cannabis has built this presence over years, focusing on specific, high-value markets.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eKey markets include Germany, Australia, and the UK.\u003c\/li\u003e\n\u003cli\u003eThey are one of only three active in-country producers in Germany.\u003c\/li\u003e\n\u003cli\u003eStrong presence in Australia following the MedReleaf Australia acquisition.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis isn't just about shipping product; it’s about navigating local compliance.\u003c\/p\u003e\n\n\u003ch\u003eImitability: The Regulatory Time-Sink\u003c\/h\u003e\n\u003cp\u003eThis network is difficult to copy because the primary barrier is time and regulatory persistence, not just capital. Building the necessary Good Manufacturing Practice (GMP) certifications and securing long-term supply agreements in places like the European Union takes years of dedicated effort and successful audits.\u003c\/p\u003e\n\u003cp\u003eTo be fair, competitors can try to acquire similar assets, but the integration risk and the time required to get new facilities approved in these strict environments still favor the incumbent.\u003c\/p\u003e\n\n\u003ch\u003eOrganization: Management’s Strategic Alignment\u003c\/h\u003e\n\u003cp\u003eManagement is clearly organized around maximizing this strength. The decision to prioritize supply to the high-margin global medical business over the lower-margin consumer segment in Canada shows clear resource allocation. The entire FY2025 strategy was built to deliver on this medical-first pivot, which resulted in the \\$244.4 million in annual medical revenue.\u003c\/p\u003e\n\u003cp\u003eThe consistent generation of positive free cash flow in the latter half of the year, alongside record adjusted EBITDA of \\$49.7 million for FY2025, suggests operational structures are supporting this high-value segment effectively.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage: Sustained, Contingent on Stability\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage here is currently \u003cstrong\u003esustained\u003c\/strong\u003e, but it carries a significant regulatory contingency. As long as Aurora Cannabis maintains its existing approvals and supply chains in core export markets like Germany and Australia, it will be very hard for competitors to catch up in the near term.\u003c\/p\u003e\n\u003cp\u003eIf onboarding takes 14+ days, churn risk rises, especially if a competitor can offer faster delivery or better pricing due to local production advantages, like the headwinds seen with Polish prescription volumes in Q4 2025.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday, focusing on inventory levels for EU shipments.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAurora Cannabis Inc. (ACB) - VRIO Analysis: EU-GMP Certified, Scalable Manufacturing Footprint\n\u003c\/h2\u003e\n\u003cp\u003e\nThe EU-GMP certified, scalable manufacturing footprint is a core operational asset for Aurora Cannabis in its international medical segment.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nAccess to high-value European medical markets is directly supported by EU-GMP status.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nFor the three months ended December 31, 2024 (Q3 2025), EU market sales reached \u003cstrong\u003e$26.3 million\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nMedical cannabis net revenue for the three months ended December 31, 2024 (Q3 2025) was \u003cstrong\u003e$68.1 million\u003c\/strong\u003e, reflecting \u003cstrong\u003e51%\u003c\/strong\u003e year-over-year growth, primarily driven by international markets including Germany.\n\u003c\/li\u003e\n\u003cli\u003e\nIn Q4 2025, international revenue doubled to represent \u003cstrong\u003e61%\u003c\/strong\u003e of global medical cannabis sales, totaling \u003cstrong\u003e$67.8 million\u003c\/strong\u003e in medical cannabis net revenue for the quarter.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe established network of certified sites provides a rare operational base.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nAurora has \u003cstrong\u003efour\u003c\/strong\u003e facilities certified as EU-GMP, including manufacturing and distribution centers.\n\u003c\/li\u003e\n\u003cli\u003e\nThe Leuna facility in Germany is noted as one of only \u003cstrong\u003ethree\u003c\/strong\u003e licensed cultivation facilities in the country.\n\u003c\/li\u003e\n\u003cli\u003e\nThe Leuna facility cultivates approximately \u003cstrong\u003e1,000 kg\u003c\/strong\u003e of cannabis flower annually for the medical supply chain.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nReplicating the multi-site, certified network requires significant time and capital investment.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNumber of EU-GMP Certified Facilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTimeframe for Leuna Upgrades\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eFive-year\u003c\/strong\u003e investment plan announced.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGerman Cultivation Capacity (Leuna Annual)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e1,000 kg\u003c\/strong\u003e of dried flower.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nOperational structure supports the utilization of the EU-GMP footprint for growth.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nThe \u003cstrong\u003efive-year\u003c\/strong\u003e investment plan at Leuna is designed to maximize capacity and adopt best practices from Canadian facilities.\n\u003c\/li\u003e\n\u003cli\u003e\nThe company's focus on global medical cannabis resulted in it delivering \u003cstrong\u003e90%\u003c\/strong\u003e of Adjusted Gross Profit dollars in Q3 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nAdjusted gross margin on medical cannabis net revenue reached \u003cstrong\u003e74%\u003c\/strong\u003e for the three months ended December 31, 2024.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe existing operational lead provides a time-based advantage in scaling EU-GMP supply.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nInternational medical revenue growth was \u003cstrong\u003e51%\u003c\/strong\u003e year-over-year in Q3 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nInternational revenue doubled to represent \u003cstrong\u003e61%\u003c\/strong\u003e of global medical cannabis sales in Q4 2025.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAurora Cannabis Inc. (ACB) - VRIO Analysis: Proprietary High-Performing Genetics and Cultivation IP\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eProprietary High-Performing Genetics and Cultivation IP\u003c\/h\u003e\u003ch\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly drives product quality and potency, which commands premium pricing in medical channels; the Aurora Alpine site achieved a record \u003cstrong\u003e33.7%\u003c\/strong\u003e potency. The adjusted gross margin before fair value adjustments on medical cannabis net revenue reached \u003cstrong\u003e70%\u003c\/strong\u003e for the three months ended March 31, 2025.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes key metrics related to the Value, Rarity, Imitability, and Organization aspects of this IP:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Component\u003c\/th\u003e\n\u003cth\u003eMetric\/Data Point\u003c\/th\u003e\n\u003cth\u003eValue\/Amount\u003c\/th\u003e\n\u003cth\u003eSource Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (Potency)\u003c\/td\u003e\n\u003ctd\u003eRecord THC Potency at Aurora Alpine\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCultivation IP Success\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (Margin)\u003c\/td\u003e\n\u003ctd\u003eMedical Cannabis Adjusted Gross Margin (3 months ended Mar 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e70%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePremium Pricing Realization\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (IP)\u003c\/td\u003e\n\u003ctd\u003eNew Proprietary Cultivars Delivered Since June 2019\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Output\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (Investment)\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D Expenses Decrease (9 months ended Dec 31, 2023 vs prior year)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.3 million\u003c\/strong\u003e decrease\u003c\/td\u003e\n\u003ctd\u003eInvestment required for IP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (Revenue Share)\u003c\/td\u003e\n\u003ctd\u003eMedical Cannabis % of Consolidated Net Revenue (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIP Exploitation Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately rare; while genetics are common, proprietary genetics proven to consistently hit high potency\/yield under controlled conditions are not easily replicated. Aurora announced it received a patent in June 2024 for US Patent \u003cstrong\u003e12,002,546\u003c\/strong\u003e, “Methods of Determining Sensitivity to Photoperiod in Cannabis”. Since June 2019, the company has delivered \u003cstrong\u003e19\u003c\/strong\u003e new proprietary cultivars from its research programs.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires long-term R\u0026amp;D investment, like that at Aurora Coast, and institutional knowledge to maintain. During the nine months ended December 31, 2023, R\u0026amp;D expenses decreased by \u003cstrong\u003e$1.3 million\u003c\/strong\u003e as compared to the prior year due to a more targeted and gated approach to product innovation. Adjusted R\u0026amp;D for the three months ended December 31, 2023, was \u003cstrong\u003e$0.9 million\u003c\/strong\u003e (in thousands). Aurora also has proprietary genetic markers patented for fruity aroma.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the IP is present, but its full exploitation depends on consistent operational execution across all facilities. The reliance on medical channels demonstrates exploitation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMedical cannabis net revenue was \u003cstrong\u003e$67.8 million\u003c\/strong\u003e in Q4 2025, delivering \u003cstrong\u003e75%\u003c\/strong\u003e of Aurora's Q4 2025 consolidated net revenue.\u003c\/li\u003e\n\u003cli\u003eMedical cannabis net revenue was \u003cstrong\u003e$70.5 million\u003c\/strong\u003e in Fiscal Q2 2026, accounting for \u003cstrong\u003e78%\u003c\/strong\u003e of total revenue.\u003c\/li\u003e\n\u003cli\u003eInternational revenue more than doubled, representing \u003cstrong\u003e61%\u003c\/strong\u003e of global medical cannabis net revenue in Q4 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; genetics can be reverse-engineered or surpassed with new breakthroughs, but it buys time now.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAurora Cannabis Inc. (ACB) - VRIO Analysis: Financial Stability: Debt-Free Core Cannabis Business \u0026amp; Cash Position\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a crucial buffer against market volatility and regulatory setbacks, allowing for strategic investment without immediate financing pressure. They ended FY2025 with \u003cstrong\u003e$185.3 million\u003c\/strong\u003e in cash.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; in a sector historically plagued by high leverage, a debt-free core cannabis operation is uncommon.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; achieved through years of deleveraging and asset sales, not something a new entrant can buy overnight.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the focus on positive FCF of \u003cstrong\u003e$9.9 million\u003c\/strong\u003e for the year shows discipline in maintaining this clean balance sheet.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; financial strength is a durable advantage in a capital-intensive, uncertain industry.\u003c\/p\u003e\n\u003cp\u003eThe financial stability is underpinned by specific, recent figures:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount (End of FY2025 \/ Annual)\u003c\/td\u003e\n\u003ctd\u003eSource Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$185.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year End March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual Free Cash Flow (FCF)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$9.9 million\u003c\/strong\u003e (Positive)\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore Cannabis Business Debt\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0\u003c\/strong\u003e (Debt-Free)\u003c\/td\u003e\n\u003ctd\u003eFiscal Year End March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNon-Recourse Debt (Bevo Farms)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$61.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of March 31, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther context on the cash position in subsequent reporting periods:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash Position at the end of Fiscal Q1 2026 (ending June 30, 2025) was reported as \u003cstrong\u003e~$182 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash and Cash Equivalents as of June 30, 2025, were reported as \u003cstrong\u003e$140.2 million\u003c\/strong\u003e, with $45.8 million in restricted cash.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe operational discipline supporting this structure is evidenced by key profitability metrics for FY2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRecord Annual Adjusted EBITDA of \u003cstrong\u003e$49.7 million\u003c\/strong\u003e, representing \u003cstrong\u003e261%\u003c\/strong\u003e Year-over-Year growth.\u003c\/li\u003e\n\u003cli\u003eGlobal Medical Cannabis Net Revenue reached a record \u003cstrong\u003e$244.4 million\u003c\/strong\u003e, a \u003cstrong\u003e39%\u003c\/strong\u003e Year-over-Year increase.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAurora Cannabis Inc. (ACB) - VRIO Analysis: Medical Brand Equity (MedReleaf, CanniMed, Pedanios)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eMedical Brand Equity (MedReleaf, CanniMed, Pedanios)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Builds patient trust and loyalty in the high-margin medical segment, which accounted for \u003cstrong\u003e75%\u003c\/strong\u003e of Q4 2025 consolidated net revenue. Medical cannabis net revenue was \u003cstrong\u003e$67.8 million\u003c\/strong\u003e in Q4 2025, a \u003cstrong\u003e48%\u003c\/strong\u003e increase year-over-year.\u003c\/p\u003e\n\u003cp\u003eRarity: Moderate; established brand names in specific medical markets (like MedReleaf in Canada or Pedanios in Europe) have inherent recognition.\u003c\/p\u003e\n\u003cp\u003eImitability: Slow; brand equity is built over time through consistent quality and physician recommendation, not just marketing spend.\u003c\/p\u003e\n\u003cp\u003eOrganization: High; management clearly prioritizes these brands, evidenced by the \u003cstrong\u003e70%\u003c\/strong\u003e adjusted gross margin on medical cannabis net revenue in Q4 2025.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Sustained; trust is hard-won and easily lost, making established medical brands sticky.\u003c\/p\u003e\n\u003cp\u003eAurora Cannabis Q4 2025 Financial Metrics:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount (CAD)\u003c\/td\u003e\n\u003ctd\u003ePercentage\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$90.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e34% increase year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Cannabis Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e75%\u003c\/strong\u003e of Total Net Revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Cannabis Adjusted Gross Margin (before FV adjustments)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e70%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated Adjusted Gross Margin (before FV adjustments)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Profit (before FV adjustments)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$54.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e62% increase year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eMedical Cannabis Segment Performance Drivers:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eIncrease in medical cannabis net revenue of \u003cstrong\u003e$22.1 million\u003c\/strong\u003e was primarily due to higher sales to Australia, Germany, Poland, and the UK, as well as increased revenue in Canada to insurance covered and self-paying patients.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eInternational revenue generation comprised over \u003cstrong\u003e61%\u003c\/strong\u003e of global medical cannabis net revenue for fiscal 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eMedical cannabis net revenue reached a record \u003cstrong\u003e$244.4 million\u003c\/strong\u003e for fiscal year 2025, representing \u003cstrong\u003e39%\u003c\/strong\u003e year-over-year growth.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAurora Cannabis Inc. (ACB) - VRIO Analysis: Operational Efficiency and Cost Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly translates to superior profitability, with a consolidated adjusted gross margin before fair value adjustments of \u003cstrong\u003e62%\u003c\/strong\u003e in Q4 2025, compared to 50% in the prior year period, driven by cost reductions across segments.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many competitors still struggle with high legacy costs, but Aurora's successful cost management, evidenced by margin expansion, is a known strength in the sector.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can copy process improvements, but Aurora’s specific, embedded efficiencies from years of optimization, such as the 27% adjusted gross margin achieved in the Consumer Cannabis segment (up from 16% YoY), are harder to match exactly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the 261% YoY growth in \u003cstrong\u003eannual\u003c\/strong\u003e Adjusted EBITDA to \u003cstrong\u003e$49.7 million\u003c\/strong\u003e proves the organization is effectively exploiting these lower costs and driving profitability.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; efficiency gains are often eroded by inflation or new technology unless continuously managed.\u003c\/p\u003e\n\u003cp\u003eKey financial metrics demonstrating operational efficiency in Q4 2025:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ4 2025 Value\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change (Q4)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated Adjusted Gross Margin (before FV)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e+1,200 basis points\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Profit (before FV)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$54.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e62%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e619%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Cannabis Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$67.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFurther evidence of organizational exploitation of efficiency:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnnual Adjusted EBITDA reached a record \u003cstrong\u003e$49.7 million\u003c\/strong\u003e, representing \u003cstrong\u003e261% YoY growth\u003c\/strong\u003e for Fiscal Year 2025.\u003c\/li\u003e\n\u003cli\u003eFiscal Year 2025 generated \u003cstrong\u003eannual positive Free Cash Flow\u003c\/strong\u003e of \u003cstrong\u003e$9.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ4 2025 Free Cash Flow was positive at \u003cstrong\u003e$2.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company sustained a strong balance sheet with approximately \u003cstrong\u003e$185.3 million\u003c\/strong\u003e of Cash and a debt-free cannabis business as of the fiscal year-end.\u003c\/li\u003e\n\u003cli\u003eBevo Plant Propagation segment improved its adjusted gross margin to \u003cstrong\u003e37%\u003c\/strong\u003e in Q4 2025, up from 25% in the prior year period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAurora Cannabis Inc. (ACB) - VRIO Analysis: Controlling Interest in Bevo Farms Ltd.\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Secures a reliable, high-quality source for propagated agricultural plants (clones\/starters), which feeds their cultivation pipeline and reduces reliance on external, potentially variable, suppliers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; vertical integration into high-quality propagation supply is not common among pure-play cannabis producers.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires significant capital investment and expertise in large-scale horticulture, which Bevo possesses.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; it’s a separate entity, but the strategic control allows Aurora to direct supply quality for its own needs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; owning the seed-to-sale input stream offers control over quality and cost that pure buyers lack.\u003c\/p\u003e\n\u003cp\u003eThe acquisition involved a controlling interest of \u003cstrong\u003e50.1%\u003c\/strong\u003e of Bevo's outstanding common shares for a total cash consideration at closing of approximately \u003cstrong\u003eC$45 million\u003c\/strong\u003e (US$33.4 million) on August 25, 2022. An additional up to \u003cstrong\u003e$12 million\u003c\/strong\u003e is payable conditionally over three years based on financial benchmarks at the Site One facility. Concurrently, Bevo entered an agreement to acquire Aurora's Aurora Sky facility, with up to \u003cstrong\u003e$25 million\u003c\/strong\u003e potentially payable by Bevo to Aurora based on milestones.\u003c\/p\u003e\n\u003cp\u003eBevo operates \u003cstrong\u003e63 acres\u003c\/strong\u003e of greenhouses in British Columbia, Canada. The management team possesses over \u003cstrong\u003e85 years\u003c\/strong\u003e of combined agricultural experience.\u003c\/p\u003e\n\u003cp\u003eFinancial performance metrics for the Bevo business segment include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eLTM Ended June 20, 2022\u003c\/td\u003e\n\u003ctd\u003eQ4 2025\u003c\/td\u003e\n\u003ctd\u003eQ2 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue (Period)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$39 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e~$10.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-Year Revenue Change\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e34%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted Gross Margin (%)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e37%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe plant propagation net revenue was wholly comprised of the Bevo business. For Q4 2025, Bevo contributed \u003cstrong\u003e$13.8 million\u003c\/strong\u003e of net revenue, a \u003cstrong\u003e32%\u003c\/strong\u003e increase compared to the prior year period. For Q2 2026, Bevo contributed \u003cstrong\u003e$11.6 million\u003c\/strong\u003e of net revenue, a \u003cstrong\u003e34%\u003c\/strong\u003e increase compared to the prior year period. Aurora's only remaining debt relating to Bevo Farms Ltd. was \u003cstrong\u003e$59.8 million\u003c\/strong\u003e as of the September 30, 2025 Financial Statements.\u003c\/p\u003e\n\u003cp\u003eStrategic implications include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eImmediate benefit from a profitable, cash flow positive business.\u003c\/li\u003e\n\u003cli\u003ePotential to drive long-term value via application of industry-leading plant propagation expertise.\u003c\/li\u003e\n\u003cli\u003eBevo's management team remains in place to execute a robust growth plan.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAurora Cannabis Inc. (ACB) - VRIO Analysis: International Regulatory and Compliance Expertise\n\u003c\/h2\u003e\n\n\u003cp\u003e\nInternational Regulatory and Compliance Expertise\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Allows Aurora to navigate complex, differing international regulatory frameworks (e.g., Germany's telemedicine partnerships) to secure and maintain market access.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; this deep, practical experience across numerous national regulatory bodies is a specialized, non-replicable asset.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Very Difficult; this is tacit knowledge gained through years of direct engagement with foreign health ministries and regulators.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this expertise is central to their strategy, which saw international revenue figures reflect this focus.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; regulatory hurdles are a permanent feature of global cannabis, making this expertise a long-term moat.\n\u003c\/p\u003e\n\n\u003cp\u003e\nSupporting Data on International Operations and Regulatory Milestones:\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Medical Cannabis Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$73.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended March 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIncrease in International Medical Net Revenue (vs prior 9 months)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$37.4 million\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eCompared to the nine months ended March 31, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue Contribution to Global Medical Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e57%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the three months ending September 30, 2024 (Q2 FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e93%\u003c\/strong\u003e increase to \u003cstrong\u003e$35 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFor the three months ending September 30, 2024 (Q2 FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGerman Cultivation Volume (Annualized)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e1,000 kg (about 2204 lb)\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAnnually since 2021 at Leuna facility under BfArM tender\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGerman Tender Lots Awarded\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eFive\u003c\/strong\u003e of the \u003cstrong\u003e13\u003c\/strong\u003e available lots\u003c\/td\u003e\n\u003ctd\u003eAwarded in a public tender by the German government\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum German Supply Commitment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4,000kg\u003c\/strong\u003e total supply\u003c\/td\u003e\n\u003ctd\u003eFrom the awarded German tender lots\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAustralian Market Size Estimate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$400 million AUD\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEstimated worth of the Australian medical market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTGA GMP Certification Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMarch 15, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDate of certification for Canadian facilities by Australia's TGA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal Operations Footprint (Historical)\u003c\/td\u003e\n\u003ctd\u003eOperations in \u003cstrong\u003e25 countries\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of September 2018\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Medical Products Developed (Since 2006)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e200\u003c\/strong\u003e different medical products\u003c\/td\u003e\n\u003ctd\u003eIncluding dried flowers and extracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\nSpecific Regulatory Engagements and Market Access:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nReceived Good Manufacturing Practice (GMP) certification from Australia's Therapeutic Goods Administration (TGA) for its River and Ridge production facilities on \u003cstrong\u003eMarch 15, 2024\u003c\/strong\u003e.\n\u003c\/li\u003e\n\u003cli\u003e\nWas one of only \u003cstrong\u003ethree companies\u003c\/strong\u003e selected in a public tender by the German Federal Institute for Drugs and Medical Devices (BfArM).\n\u003c\/li\u003e\n\u003cli\u003e\nSince 2021, the Leuna, Germany facility has been cultivating approximately \u003cstrong\u003e1,000 kg (about 2204 lb)\u003c\/strong\u003e of medical cannabis flower annually.\n\u003c\/li\u003e\n\u003cli\u003e\nIn Q2 FY2025 (three months ending September 30, 2024), international revenue reached \u003cstrong\u003e$35 million\u003c\/strong\u003e, exceeding Canadian Medical revenue for the first time.\n\u003c\/li\u003e\n\u003cli\u003e\nIn Q1 FY2024 (three months to June 30th), global medical business sales increased \u003cstrong\u003e14%\u003c\/strong\u003e year-on-year to \u003cstrong\u003eC$41.6m\u003c\/strong\u003e, representing \u003cstrong\u003e55%\u003c\/strong\u003e of total net revenues.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAurora Cannabis Inc. (ACB) - VRIO Analysis: Diversified Brand Portfolio (Medical and Consumer)\n\u003c\/h2\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eProvides optionality to pivot resources based on market profitability, as seen by prioritizing medical over the declining consumer segment in the comparison of Q1 FY2025 to Q1 FY2026 net revenue figures. Medical cannabis net revenue increased from \u003cstrong\u003e$47.2 million\u003c\/strong\u003e in Q1 FY2025 to \u003cstrong\u003e$64.8 million\u003c\/strong\u003e in Q1 FY2026, representing a \u003cstrong\u003e37%\u003c\/strong\u003e year-over-year growth in the latest quarter, while consumer cannabis net revenue decreased from \u003cstrong\u003e$11.5 million\u003c\/strong\u003e in Q1 FY2025 to \u003cstrong\u003e$7.9 million\u003c\/strong\u003e in Q1 FY2026, a \u003cstrong\u003e32%\u003c\/strong\u003e decrease year-over-year.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; many companies have brands, but Aurora’s portfolio spans both high-margin medical (MedReleaf) and established Canadian adult-use (San Rafael '71). The medical segment achieved an Adjusted Gross Margin before fair value adjustments of \u003cstrong\u003e74%\u003c\/strong\u003e in Q3 FY2025, and \u003cstrong\u003e69%\u003c\/strong\u003e in Q1 FY2026, while the consumer segment reported an Adjusted Gross Margin before fair value adjustments of \u003cstrong\u003e33%\u003c\/strong\u003e in Q1 FY2026.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eSlow; building a portfolio of recognized names across different segments takes time and acquisition history. The portfolio includes medical brands such as MedReleaf, CanniMed, Aurora, and Whistler Medical Marijuana Co., and adult-use brands including Drift, San Rafael '71, Daily Special, Tasty's, Being, and Greybeard.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eModerate; the organization has shown it can manage the portfolio by strategically de-emphasizing the consumer side to boost overall margins. The decrease in consumer cannabis net revenue to \u003cstrong\u003e$7.9 million\u003c\/strong\u003e in Q1 FY2026 was an expected result of the continued decision to prioritize supply to the higher margin medical cannabis business.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; brand relevance can fade, but the existing portfolio provides a strong base to launch new, high-margin products. Medical cannabis comprised \u003cstrong\u003e66%\u003c\/strong\u003e of Aurora's Q1 FY2026 consolidated net revenue, up from \u003cstrong\u003e57%\u003c\/strong\u003e in Q1 FY2025, and accounted for approximately \u003cstrong\u003e91%\u003c\/strong\u003e of adjusted gross profit in both periods.\u003c\/p\u003e\n\u003cp\u003eThe segment performance comparison for the three months ended June 30, 2025 (Q1 FY2026) versus the three months ended June 30, 2024 (Q1 FY2025) is detailed below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 FY2026 (3 Months Ended June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eQ1 FY2025 (3 Months Ended June 30, 2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$98.0 million\u003c\/strong\u003e or \u003cstrong\u003e$104.5 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$74.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Cannabis Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$64.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$47.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Cannabis Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Cannabis % of Total Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e66%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e57%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Cannabis Adjusted Gross Margin (pre-FV)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e69%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e61%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumer Cannabis Adjusted Gross Margin (pre-FV)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eKey brand-related financial contributions and operational focus areas:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMedical cannabis net revenue growth of \u003cstrong\u003e37%\u003c\/strong\u003e year-over-year in Q1 FY2026, driven by higher sales to Australia, Germany, Poland, and the UK.\u003c\/li\u003e\n\u003cli\u003eConsumer cannabis net revenue decreased by \u003cstrong\u003e32%\u003c\/strong\u003e year-over-year in Q1 FY2026.\u003c\/li\u003e\n\u003cli\u003eAurora ended Q1 FY2026 with \u003cstrong\u003e$186,000,000\u003c\/strong\u003e in cash and cash equivalents and no cannabis business debt.\u003c\/li\u003e\n\u003cli\u003eThe company generated positive Free Cash Flow of \u003cstrong\u003e$9,200,000\u003c\/strong\u003e in Q1 FY2026.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516105187477,"sku":"acb-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/acb-vrio-analysis.png?v=1740149782","url":"https:\/\/dcf-model.com\/products\/acb-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}